ITI MF

CATEGORY OF SCHEME	Sectoral/Thematic
INVESTMENT OBJECTIVE	The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Inception Date (Date of Allotment):	08-Nov-21
Benchmark:	Nifty Healthcare TRI
Minimum Application Amount:	Rs.5,000/- and in multiples of Rs. 1/- thereafter
Load Structure:	Entry Load: Nil Exit Load: 1% if redeemed or switched out on or before completion of 12 months from the date of allotment of units · Nil, if redeemed or switched out after completion of 12 months from the date of allotment of units.
Total Expense Ratio (TER):	Including Additional Expenses and Goods and Service Tax on Management Fees Regular Plan: 2.34% Direct Plan: 0.43%
Fund Manager	Mr. Rohan Korde (Since 08-Nov-21) Total Experience: 19 years Mr. Dhimant Shah (Since 01 December 2022) Total Experience : 26 years

AUM (in Rs. Cr):	138.52
AAUM (in Rs. Cr):	137.68
% of top 5 holdings:	47.69%
% of top 10 holdings:	65.86%
No. of scrips:	33

Standard Deviation^:	NA
Beta^:	NA
*Sharpe Ratio^:**	NA
Average P/B	5.39
Average P/E	42.05
Portfolio Beta	0.81
^Scheme has not completed 3 years hence NA * Risk free rate: 6.40 (Source: FIMMDA MIBOR)

	Regular Plan (in Rs.)	Direct Plan (in Rs.)
Growth:	9.5867	9.9271
IDCW:	9.5867	9.9271

Name of the Instrument	% to NAV	% to NAV Derivatives
Equity & Equity Related Total	97.51
Chemicals	4.63
Astec LifeSciences Limited	3.07
Gujarat Fluorochemicals Limited	1.56
Diversified	0.99
TTK Healthcare Limited	0.99
Financial Services	0.55
SBI Life Insurance Company Limited	0.55
Healthcare	91.34
Sun Pharmaceutical Industries Limited	21.00
Cipla Limited	7.84
Max Healthcare Institute Limited	7.61
Torrent Pharmaceuticals Limited	5.83
Apollo Hospitals Enterprise Limited	5.42
Dr. Reddy's Laboratories Limited	5.11
Suven Pharmaceuticals Limited	3.62
Syngene International Limited	3.34
Lupin Limited	3.02
Alkem Laboratories Limited	2.55
Divi's Laboratories Limited	2.53
Mankind Pharma Limited	2.40
Zydus Lifesciences Limited	2.26
FDC Limited	2.15
IPCA Laboratories Limited	1.67
Aster DM Healthcare Limited	1.64
Ami Organics Limited	1.58
JB Chemicals & Pharmaceuticals Limited	1.56
Rainbow Childrens Medicare Limited	1.31
Healthcare Global Enterprises Limited	1.23
Narayana Hrudayalaya Limited	1.11
Natco Pharma Limited	1.08
Fortis Healthcare Limited	1.04
Ajanta Pharma Limited	1.04
Advanced Enzyme Technologies Limited	0.84
Gland Pharma Limited	0.71
Abbott India Limited	0.69
GlaxoSmithKline Pharmaceuticals Limited	0.62
Dr. Lal Path Labs Limited	0.53
Short Term Debt & Net Current Assets	2.49

Top Ten Holdings

Period	Fund Returns (%)	Benchmark Returns (%)	Additional Benchmark Returns (%)	Benchmark (Rs)	Fund (Rs)	Additional Benchmark Returns (Rs)
Regular - Growth
Last 1 Year	8.51%	6.01%	12.94%	10,851	10,601	11,294
Since Inception	-2.67%	-2.51%	2.81%	9,587	9,611	10,442
Direct - Growth
Last 1 Year	10.86%	6.01%	12.94%	11,086	10,601	11,294
Since Inception	-0.47%	-2.51%	2.81%	9,927	9,611	10,442

Past performance may or may not be sustained in future. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. Fund Managers: Mr. Rohan Korde (Managing since 08-Nov-21) and Mr. Dhimant Shah (Managing since 01-December-22). Inception date of the scheme is (08-Nov-2021) . Face Value per unit: Rs. 10.

Period	Amount Invested	Fund Value ()	Fund Returns (%)	Benchmark Value ()	Benchmark Returns (%)	Additional Benchmark Value ()	Additional Benchmark Returns (%)
Regular - Growth
Last 1 Year	120000	125283	8.30%	124563	7.16%	128147	12.89%
Since Inception	190000	194537	2.88%	192995	1.90%	203984	8.87%
Direct - Growth
Last 1 Year	120000	126808	10.74%	124563	7.16%	128147	12.89%
Since Inception	190000	198134	5.16%	192995	1.90%	203984	8.87%

Past performance may or may not be sustained in future. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. For SIP returns, monthly investment of Rs.10,000 invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).